Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SAR156597 in Idiopathic Pulmonary Fibrosis
2014-003933-24Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of romilkimab in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Sanofi. Primary endpoint: Absolute change from baseline in percent predicted FVC at 52 weeks. Started Feb 2015; status: completed.
02
Drugs
romilkimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2014-003933-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003933-24.